Journal: Current opinion in clinical nutrition and metabolic care
This review evaluates current evidence on omega-3 polyunsaturated fatty acids (PUFAs), emphasizing that their widespread use contrasts with inconsistent and often modest clinical benefits.
Key points:
- Reported benefits: Recent clinical studies suggest potential advantages in cardiometabolic disease, inflammation, cognitive function, pregnancy outcomes, certain cancers, and some neuropsychiatric conditions. However, data in generally healthy individuals are weaker, and broad dietary/supplementation recommendations are not firmly supported.
- Heterogeneous response: Inter-individual variability in clinical effect is substantial and appears to be influenced by:
- Genetic differences
- Gut microbiome composition
- Oxidative stress status
- Background diet
- Variations in supplementation regimens (dose, formulation, duration)
- Product quality and oxidation: Many omega-3 products are susceptible to oxidative degradation. Oxidized preparations may have diminished or absent benefit and could potentially be harmful, yet oxidation status is rarely reported in trials or on commercial products. The long-term health impact of chronically ingesting oxidized lipids in humans remains unclear.
- Recommendations for research and practice:
- Move toward biomarker-guided, personalized omega-3 interventions, incorporating baseline blood omega-3 status.
- Require better characterization and reporting of:
- Formulation (e.g., type and form of omega-3s)
- Oxidation status and quality of products, including supplements and fortified foods
- Baseline participant characteristics relevant to omega-3 biology.
- Standardization in these areas is needed to clarify dose–response relationships and optimize therapeutic efficacy.